Biotech closes on $9M for stem cell, cord blood research

09/14/2007 | American City Business Journals

Aldagen has raised $9 million in funding to use for its research with stem cells derived from bone marrow, blood and umbilical cords. The biotech company currently has three drugs trials under way for improving safety in cord blood transfusions and treating advanced heart failure and blocked extremities.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA